Trump's federal grant overhaul plan draws strong pushback

What the proposal would change

The Trump administration’s proposed rewrite of federal grant rules is drawing unusually strong pushback because it would move final influence over grant decisions away from independent scientific peer review and toward political appointees.

Under the Office of Management and Budget proposal, senior political appointees would review grant requests for alignment with law and presidential priorities. Scientific peer review would still exist, but it would be advisory rather than decisive.

That would be a major change in how federal research money is allocated. For decades, peer review has been the main filter for deciding which projects get support, especially in medicine, biotech and other science fields.

The proposal would apply governmentwide, not just at one agency. That gives the fight broader significance because it could affect how billions of dollars in grants are awarded across the federal system.

How the backlash built

The rulemaking was posted in late May, according to Axios, and researchers began raising alarms soon after reporting in early June described peer review as advisory and political appointees as handling pre-issuance review for discretionary grants.

By July 9, Axios reported the proposal had received more than 93,000 public comments. That is an unusually large response for a grantmaking rule and suggests the issue has become a broader political and scientific flash point.

The comment total also shows how much attention the proposal has drawn from researchers, universities, biotech companies, pharmaceutical industry groups and patient advocacy organizations.

Those groups argue that shifting final authority to appointees would politicize scientific funding and make it harder to preserve independent judgment in research decisions.

What the administration says

The administration has defended the rewrite as a transparency and accountability measure. AP reported that the White House says the changes would ensure grants comply with legal requirements and the president’s priorities.

OMB has gone further in its public defense, saying in a statement quoted by Axios that federal grants had been politicized under the prior administration to promote a far-left DEI agenda.

That is the core clash in the dispute. The administration says the overhaul would correct politicization and strengthen oversight. Critics say it would replace expert review with political control.

Axios also reported that the proposal was still not finalized and that a senior administration official said it remained controversial inside the administration.

Why the stakes are high

The stakes extend well beyond the rule text. The proposal could change how billions of dollars in federal grants are distributed, especially in health and research programs.

Scientists and industry groups warn that even the prospect of political review could delay or deter applications, particularly in fields that depend heavily on public funding for early-stage work.

Universities, biotech firms and medical groups also worry that a more politicized process could make federal funding less predictable. That could affect hiring, project planning and the willingness of institutions to pursue ambitious research.

The broader concern is competitiveness. Federal grants help support basic research and translational work that private investors often avoid because the payoff is uncertain or too far in the future.

What happens next

The proposal is not yet final, so the next question is whether OMB keeps it in its current form or revises it after the comment period.

Another open issue is whether agencies would carve out exceptions for research grants or health programs if the rule goes forward.

For now, the dispute is likely to keep playing out through public comments, agency review and pressure from researchers, universities and industry groups.

The proposal has already become part of a larger fight over whether political appointees should have final influence over scientific funding decisions at all.

The answer to that question will shape not only this rule, but the future balance between expert peer review and White House control across the federal grantmaking system.